Health
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, ...
2025-01-13 21:50
1099
CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion
- R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore -based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets - Transacti...
2025-01-13 19:25
1887
XingImaging Opens State-of-the-Art Research Facility in New Haven, Connecticut
NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven, Connecticut. The facility includes a clinic to recrui...
2025-01-13 18:00
900
CTF Life Becomes Title Sponsor of "Fencing Plus" Training Programme by Kai Tak Sports Initiative Nurturing a New Generation of Sports Elites for Hong Kong Gearing Up for World Championships
HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Chow Tai Fook Life Insurance Company Limited (CTF Life) is pleased to become the Title Sponsor of "Fencing Plus" Training Programme by Kai Tak Sports Initiative, cultivating a new generation of elite fencing athletes for Hong Kong as future world champions...
2025-01-13 16:57
2132
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended31 December 2024 (Q4 2024). Sustained revenue growth * Q...
2025-01-13 15:12
1804
Scintimun® Commercialization Partnership with Curium Pharma
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99m Tc-be...
2025-01-13 13:08
1304
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...
2025-01-13 09:05
2435
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...
2025-01-13 09:05
2038
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Suppl...
2025-01-13 08:00
1665
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next...
2025-01-13 06:34
1886
Neusoft Education officially renamed as " Neutech Group Limited ", accelerating the advancement of the "education-healthcare-wellness and mind tour" strategy in a new stage
HONG KONG, Jan. 11, 2025 /PRNewswire/ -- On 9 January, Neusoft Education (09616.HK) announced that the Company's English name will change from "Neusoft Education Technology Co. Limited" to "Neutech Group Limited". The name change will take effect on the same day. According to the announcement, t...
2025-01-12 15:14
2752
Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs
* The legacy of Duke-NUS' founding donor, the Estate of Khoo Teck Puat, continues with a transformativeS$5.5 million gift towards research. * The HEAD Foundation steps up with a S$200,000 scholarship, underpinning Duke-NUS' commitment to developing medical expertise. SINGAPORE, Jan. 11, 2025 ...
2025-01-11 22:15
3438
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agr...
2025-01-11 17:07
4054
Corn Next Launches CornNext-17: A Groundbreaking Sustainable Solution to Plastic Pollution
IRVINE, Calif., Jan. 11, 2025 /PRNewswire/ -- Corn Next, a leader in sustainable innovation and biodegradable solutions, has officially launched CornNext-17, a game-changing bio-based material designed to combat the global plastic pollution crisis. Accompanying this launch is the release of th...
2025-01-11 05:53
4182
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
* Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau * No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo * Enrollment o...
2025-01-11 01:30
2107
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...
2025-01-11 00:00
2263
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...
2025-01-10 22:00
1559
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immuno...
2025-01-10 21:01
3616
Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress
Announces Major Milestones at the JPM Healthcare Conference
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in
neurotherapeutics discovery and development, has officially rebranded asXylo Bio
2025-01-10 21:00
992
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Adm...
2025-01-10 17:00
4064
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 318 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 291 media titles]
2025-01-13 10:44
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 285 media titles]
2025-01-10 16:04VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 278 media titles]
2025-01-09 18:26
LANDI Global Unveils Flagship Cx20: Elevating business efficiency and customer experience with a next-generation Windows-powered terminal
[Picked up by 272 media titles]
2025-01-11 22:30
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
19992
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6446
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5375
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4854
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4827
